Researchers compared four exome capture platforms using the DNBSEQ high-throughput sequencer to benchmark coverage, on-target rates and variant-calling performance. The study provides sequencing centers and biotech companies with comparative data to guide platform selection for clinical and research exome workflows. The authors highlight trade-offs among capture breadth, uniformity and cost-per-sample—technical details that labs and diagnostics developers will use to align platform choice with pipeline requirements.